Phospholipid reference standards are the “cornerstone” of research and development and quality testing in the pharmaceutical industry, with their availability and reliability directly impacting the quality of development across phospholipid-related sectors. As a supplier that has repeatedly won bids for the procurement of raw materials for phospholipid reference standards from the National Institute for Food and Drug Control (hereinafter referred to as “NIFDC”), Guangyao Hanfang (Zhuhai Hengqin) Pharmaceutical Co., Ltd. (a wholly owned subsidiary of Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., hereinafter referred to as “Guangyao Hanfang”) is shouldering the important responsibility of providing high-quality phospholipid raw materials to the industry and supporting the formulation of national standards.
Guangyao Hanfang’s products—including egg yolk phosphatidylethanolamine, hemolytic egg yolk phosphatidylethanolamine, hemolytic phosphatidylcholine, egg yolk phosphatidylcholine, and phosphatidylinositol—are used as raw materials for NIFDC’s phospholipid reference standards. After rigorous screening and quality assessment, these products have become a key component of the national pharmaceutical quality standard system. With their high purity and excellent stability, these raw materials provide a solid foundation for NIFDC to prepare legally recognized phospholipid reference standards, helping address longstanding industry challenges such as inconsistent standards and difficulties in mutually recognizing test results, thereby driving the standardization of phospholipid-related pharmaceutical products in China from the source.
Currently, Guangyao Hanfang has achieved large-scale production of the aforementioned phospholipid products at the 100-gram level, with purity levels meeting or exceeding NIFDC’s tender requirements; meanwhile, similar domestic and international companies generally remain at the milligram-level small-batch supply stage. Leveraging this advantage in scaled production technology, Guangyao Hanfang has not only broken the long-standing monopoly held by foreign firms on high-purity phospholipid raw materials but has also taken the lead in ensuring stable, large-volume domestic supply, providing a solid guarantee for the sustainable updating of the national reference standard system.
Empowering Industrial Upgrading: Activating Industry Vitality with Premium Raw Materials
The quality of phospholipid reference standards is crucial not only for the scientific rigor and safety of drug development but also for the reliability of quality control systems. The phospholipid raw materials supplied by Guangyao Hanfang excel in multiple key indicators, rivaling comparable international products while offering significant cost advantages, demonstrating dual competitiveness characterized by “high quality + high cost-effectiveness.”
This dual advantage of “high quality + high cost-effectiveness” not only provides a more reliable experimental foundation for drug development, making research outcomes more precise and R&D cycles more controllable, but also helps manufacturing enterprises enhance their quality control capabilities, propelling domestically produced pharmaceuticals toward higher standards. By consistently delivering premium phospholipid products, Guangyao Hanfang is injecting vital momentum into the upgrading of China’s pharmaceutical industry chain, advancing the process of domestic substitution and strengthening the core competitiveness of Chinese pharmaceuticals in the global market.
From supporting the formulation of national standards and breaking international monopolies to driving high-quality industrial development, Guangyao Hanfang has remained committed to deepening its expertise in the phospholipid field as a dedicated contributor to the industry. Looking ahead, the company will continue expanding its product portfolio and optimizing its preparation processes, striving to provide the industry with more comprehensive and higher-quality standardized solutions, thus helping China’s pharmaceutical sector achieve high-quality, sustainable growth.
